Kangtai Bio
Kangtai Bio
Kangtai Bio a famous international pharmaceutical company
Kangtai Bio is one of the first high-tech enterprises in Shenzhen, mainly engaged in the development, production and sales of biological products. It has a team of vaccine industry professionals who have made important breakthroughs in the research and development of new vaccines. The production line is imported from Merck, a famous international pharmaceutical company, and its safety and efficacy have been guaranteed, and the products have covered 31 provinces, municipalities and autonomous regions.
- All
- News
- Analysis
- Research
In depth
Briefing Jan 13, 2022 10:05 AM
· Healthcare
West Lake Omei won hundreds of millions of yuan of pre-A round of financing to help clinical diagnosis and AI new drug research and development based on proteome big data
Briefing Jan 12, 2022 09:28 AM
· Healthcare
Zhenge biology obtained US $100 million in round C financing, led by Goldman Sachs and Sofina
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Jan 10, 2022 09:00 PM
· Healthcare
Bristol Myers Squibb entered the development of IPSC derived allogeneic cell therapy with more than US $3 billion
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
Briefing Jan 10, 2022 09:37 AM
· Healthcare
Synthetic biology enterprise Lanjing microorganism completed a total of 1.5 billion yuan of Series B financing
Briefing Jan 06, 2022 05:02 PM
· Healthcare
Yourui pharmaceutical acquired Zhongjian pharmaceutical to create a special pharmaceutical company driven by two wheels of innovative pipeline R & D and commercialization of mature products
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Jul 23, 2021 10:13 AM
· Healthcare
Pharmaceutical and biological stocks fell sharply in early trading
See more
Related Companies
EqualOcean Analysis
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.